Ontology highlight
ABSTRACT: Background
Sembragiline is a potent, selective, long-acting, and reversible MAO-B inhibitor developed as a potential treatment for Alzheimer's disease (AD).Objective
To evaluate the safety, tolerability, and efficacy of sembragiline in patients with moderate AD.Methods
In this Phase II study (NCT01677754), 542 patients with moderate dementia (MMSE 13-20) on background acetylcholinesterase inhibitors with/without memantine were randomized (1:1:1) to sembragiline 1 mg, 5 mg, or placebo once daily orally for 52 weeks.Results
No differences between treated groups and placebo in adverse events or in study completion. The primary endpoint, change from baseline in ADAS-Cog11, was not met. At Week 52, the difference between sembragiline and placebo in ADAS-Cog11 cha
SUBMITTER: Nave S
PROVIDER: S-EPMC5523913 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature